NEW YORK (TheStreet) -- Shares of Conatus Pharmaceuticals (CNAT) - Get Report are up by 12.54% to $6.47 in mid-morning trading on Thursday, after the company reported positive phase 2 results from the study of its hypertension relief treatment candidate, emricasan.

The drug met its primary endpoint of achieving a statistically significant change from baseline measurement of pressure in the portal vein in patients with liver cirrhosis and severe portal hypertension, the company said.

Portal Hypertension is elevated blood pressure in the major vein feeding into the liver.

The study enrolled 22 patients with portal hypertension caused by nonalcoholic steatohepatitis (NASH) or the hepatitis C virus.

Image placeholder title

CNAT

data by

YCharts